Journal for ImmunoTherapy of Cancer (Nov 2021)
208 RTX-224, an engineered allogeneic red cell therapeutic expressing 4–1BBL and IL-12, activates immune cells in blood and spleen to promote tumor growth inhibition in mice
Abstract
No abstracts available.